Leonard B. Saltz

84.7k total citations · 11 hit papers
544 papers, 38.3k citations indexed

About

Leonard B. Saltz is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Leonard B. Saltz has authored 544 papers receiving a total of 38.3k indexed citations (citations by other indexed papers that have themselves been cited), including 417 papers in Oncology, 178 papers in Surgery and 129 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Leonard B. Saltz's work include Colorectal Cancer Treatments and Studies (243 papers), Colorectal and Anal Carcinomas (134 papers) and Colorectal Cancer Surgical Treatments (131 papers). Leonard B. Saltz is often cited by papers focused on Colorectal Cancer Treatments and Studies (243 papers), Colorectal and Anal Carcinomas (134 papers) and Colorectal Cancer Surgical Treatments (131 papers). Leonard B. Saltz collaborates with scholars based in United States, France and United Kingdom. Leonard B. Saltz's co-authors include José G. Guillem, Robert J. Mayer, Philip B. Paty, Bruce D. Minsky, Nancy E. Kemeny, David P. Kelsen, Jinru Shia, Martin R. Weiser, Donna Niedzwiecki and Arié Figer and has published in prestigious journals such as New England Journal of Medicine, Cell and The Lancet.

In The Last Decade

Leonard B. Saltz

525 papers receiving 37.3k citations

Hit Papers

Irinotecan plus Fluorouracil and Leucovorin for Metastati... 2000 2026 2008 2017 2000 2008 2004 2006 2005 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
    2000 2.4k citations Leonard B. Saltz et al. profile →
  2. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
    2008 2.3k citations Leonard B. Saltz, Stephen Clarke et al. Journal of Clinical Oncology profile →
  3. Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
    2004 1.4k citations Leonard B. Saltz, Robert J. Mayer et al. Journal of Clinical Oncology profile →
  4. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    2006 948 citations Ghassan K. Abou‐Alfa, Arié Figer et al. Journal of Clinical Oncology profile →
  5. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
    2005 848 citations Jinru Shia, Nancy E. Kemeny et al. Journal of Clinical Oncology profile →
  6. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
    2008 652 citations Jim Cassidy, Stephen Clarke et al. Journal of Clinical Oncology profile →
  7. Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803
    2006 537 citations Jeffrey A. Meyerhardt, Donna Niedzwiecki et al. Journal of Clinical Oncology profile →
  8. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
    2015 513 citations Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology profile →
  9. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
    2016 434 citations Qian Shi, Leonard B. Saltz et al. profile →
  10. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
    2018 369 citations Maeve A. Lowery, Ryan Ptashkin et al. Clinical Cancer Research profile →
  11. Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
    2015 340 citations Leonard B. Saltz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leonard B. Saltz United States 105 28.0k 10.3k 9.6k 6.6k 6.0k 544 38.3k
Al B. Benson United States 94 18.9k 0.7× 8.7k 0.8× 8.7k 0.9× 3.5k 0.5× 4.5k 0.7× 492 31.0k
Malcolm J. Moore Canada 72 25.0k 0.9× 9.5k 0.9× 10.6k 1.1× 7.6k 1.1× 4.8k 0.8× 358 37.0k
Michel Ducreux France 91 26.0k 0.9× 11.8k 1.1× 10.7k 1.1× 4.6k 0.7× 4.0k 0.7× 628 38.9k
Bengt Glimelius Sweden 92 30.4k 1.1× 18.0k 1.8× 9.9k 1.0× 3.4k 0.5× 6.2k 1.0× 700 41.7k
Heinz‐Josef Lenz United States 83 24.6k 0.9× 5.4k 0.5× 9.2k 1.0× 9.7k 1.5× 8.2k 1.4× 860 35.9k
John D. Hainsworth United States 82 21.5k 0.8× 5.3k 0.5× 12.3k 1.3× 10.1k 1.5× 7.0k 1.2× 631 37.1k
Filippo de Braud Italy 74 17.9k 0.6× 5.6k 0.5× 8.8k 0.9× 5.7k 0.9× 3.3k 0.6× 754 26.7k
Armando Santoro Italy 87 17.8k 0.6× 3.8k 0.4× 13.8k 1.4× 5.6k 0.8× 8.8k 1.5× 924 34.7k
Josep Tabernero Spain 102 34.3k 1.2× 8.1k 0.8× 14.7k 1.5× 14.4k 2.2× 9.5k 1.6× 1.1k 50.8k
James L. Abbruzzese United States 112 25.9k 0.9× 7.9k 0.8× 8.6k 0.9× 16.1k 2.4× 3.5k 0.6× 513 43.3k

Countries citing papers authored by Leonard B. Saltz

Since Specialization
Citations

This map shows the geographic impact of Leonard B. Saltz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard B. Saltz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard B. Saltz more than expected).

Fields of papers citing papers by Leonard B. Saltz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonard B. Saltz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard B. Saltz. The network helps show where Leonard B. Saltz may publish in the future.

Co-authorship network of co-authors of Leonard B. Saltz

This figure shows the co-authorship network connecting the top 25 collaborators of Leonard B. Saltz. A scholar is included among the top collaborators of Leonard B. Saltz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard B. Saltz. Leonard B. Saltz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cercek, Andrea, Jinru Shia, Jill Weiss, et al.. (2024). Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA3512–LBA3512. 35 indexed citations
3.
Lowery, Maeve A., Ryan Ptashkin, Emmet Jordan, et al.. (2018). Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical Cancer Research. 24(17). 4154–4161. 369 indexed citations breakdown →
4.
Cercek, Andrea, Maria Ignez Braghiroli, Joanne F. Chou, et al.. (2017). Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical Cancer Research. 23(16). 4753–4760. 58 indexed citations
5.
Ptashkin, Ryan, Carlos Pagan, Rona Yaeger, et al.. (2017). Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research. 15(6). 708–713. 19 indexed citations
6.
Yaeger, Rona, Zhan Yao, David M. Hyman, et al.. (2017). Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research. 77(23). 6513–6523. 60 indexed citations
7.
Yaeger, Rona, Andrea Cercek, Eileen M. O’Reilly, et al.. (2015). Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research. 21(6). 1313–1320. 221 indexed citations
8.
Kopetz, Scott, Jayesh Desai, Emily Chan, et al.. (2015). Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer. Journal of Clinical Oncology. 33(34). 4032–4038. 513 indexed citations breakdown →
9.
Hechtman, Jaclyn F., Ahmet Zehir, Rona Yaeger, et al.. (2015). Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research. 14(3). 296–301. 43 indexed citations
10.
Yu, Kenneth H., Manuel Hidalgo, Ghassan K. Abou‐Alfa, et al.. (2014). Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. Clinical Cancer Research. 20(20). 5281–5289. 41 indexed citations
11.
McCleary, Nadine J., Jeffrey A. Meyerhardt, Erin Green, et al.. (2013). Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. Journal of Clinical Oncology. 31(20). 2600–2606. 157 indexed citations
12.
Warren, Robert S., Chloé E. Atreya, Donna Niedzwiecki, et al.. (2013). Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. Clinical Cancer Research. 19(20). 5777–5787. 32 indexed citations
13.
Yaeger, Rona & Leonard B. Saltz. (2012). BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy. Journal of the National Comprehensive Cancer Network. 10(11). 1456–1458. 12 indexed citations
14.
Ogino, Shuji, Kaori Shima, Jeffrey A. Meyerhardt, et al.. (2011). Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clinical Cancer Research. 18(3). 890–900. 207 indexed citations
15.
Lambrechts, Diether, D.W. Miles, Leonard B. Saltz, et al.. (2011). Genetic Markers in Relation to Bevacizumab-induced Hypertension. European Journal of Cancer. 47. 1 indexed citations
16.
Poultsides, George A., Elliot L. Servais, Leonard B. Saltz, et al.. (2009). Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. Journal of Clinical Oncology. 27(20). 3379–3384. 265 indexed citations
17.
Reidy‐Lagunes, Diane, Laura H. Tang, & Leonard B. Saltz. (2009). Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nature Reviews Clinical Oncology. 6(3). 143–152. 25 indexed citations
18.
Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2008). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 26(12). 2013–2019. 2275 indexed citations breakdown →
19.
Pérez-Soler, Román, Jean Pierre Delord, Allan C. Halpern, et al.. (2005). HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. The Oncologist. 10(5). 345–356. 215 indexed citations
20.
Kelsen, David P., Martin S. Karpeh, Gary K. Schwartz, et al.. (1996). Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.. Journal of Clinical Oncology. 14(6). 1818–1828. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Al B. Benson Breakdown of academic impact, for papers by Malcolm J. Moore Breakdown of academic impact, for papers by Michel Ducreux Breakdown of academic impact, for papers by Bengt Glimelius Breakdown of academic impact, for papers by Heinz‐Josef Lenz Breakdown of academic impact, for papers by John D. Hainsworth Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Armando Santoro Breakdown of academic impact, for papers by Josep Tabernero Breakdown of academic impact, for papers by James L. Abbruzzese
Rankless by CCL
2026